KR102919268B1 - Iga 신병증을 치료하기 위한 부데소니드를 포함하는 약학적 조성물 - Google Patents

Iga 신병증을 치료하기 위한 부데소니드를 포함하는 약학적 조성물

Info

Publication number
KR102919268B1
KR102919268B1 KR1020247027521A KR20247027521A KR102919268B1 KR 102919268 B1 KR102919268 B1 KR 102919268B1 KR 1020247027521 A KR1020247027521 A KR 1020247027521A KR 20247027521 A KR20247027521 A KR 20247027521A KR 102919268 B1 KR102919268 B1 KR 102919268B1
Authority
KR
South Korea
Prior art keywords
budesonide
pharmaceutical composition
released
minutes
dissolution medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247027521A
Other languages
English (en)
Korean (ko)
Other versions
KR20240141771A (ko
Inventor
에바 크리스티나 리젤
레나 마르가레타 페레스웨토프-모라스
카리 샌드볼드
크리스티안 올레 안드레아스 페데르센
Original Assignee
칼리디타스 테라퓨틱스 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=85076189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102919268(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB2217146.6A external-priority patent/GB202217146D0/en
Priority claimed from GBGB2217150.8A external-priority patent/GB202217150D0/en
Application filed by 칼리디타스 테라퓨틱스 에이비 filed Critical 칼리디타스 테라퓨틱스 에이비
Priority to KR1020247043208A priority Critical patent/KR20250008979A/ko
Publication of KR20240141771A publication Critical patent/KR20240141771A/ko
Application granted granted Critical
Publication of KR102919268B1 publication Critical patent/KR102919268B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247027521A 2022-01-24 2023-01-24 Iga 신병증을 치료하기 위한 부데소니드를 포함하는 약학적 조성물 Active KR102919268B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247043208A KR20250008979A (ko) 2022-01-24 2023-01-24 Iga 신병증을 치료하기 위한 부데소니드를 포함하는 약학적 조성물

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263302226P 2022-01-24 2022-01-24
US202263302216P 2022-01-24 2022-01-24
US63/302,216 2022-01-24
US63/302,226 2022-01-24
GBGB2217146.6A GB202217146D0 (en) 2022-11-16 2022-11-16 New pharmaceutical compositions
GB2217150.8 2022-11-16
GB2217146.6 2022-11-16
GBGB2217150.8A GB202217150D0 (en) 2022-11-16 2022-11-16 New pharmaceutical compositions
PCT/EP2023/051680 WO2023139285A1 (en) 2022-01-24 2023-01-24 Pharmaceutical composition comprising budesonide for treating iga nephropathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247043208A Division KR20250008979A (ko) 2022-01-24 2023-01-24 Iga 신병증을 치료하기 위한 부데소니드를 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
KR20240141771A KR20240141771A (ko) 2024-09-27
KR102919268B1 true KR102919268B1 (ko) 2026-01-27

Family

ID=85076189

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247027521A Active KR102919268B1 (ko) 2022-01-24 2023-01-24 Iga 신병증을 치료하기 위한 부데소니드를 포함하는 약학적 조성물
KR1020247043208A Pending KR20250008979A (ko) 2022-01-24 2023-01-24 Iga 신병증을 치료하기 위한 부데소니드를 포함하는 약학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247043208A Pending KR20250008979A (ko) 2022-01-24 2023-01-24 Iga 신병증을 치료하기 위한 부데소니드를 포함하는 약학적 조성물

Country Status (14)

Country Link
US (10) US11896719B2 (enExample)
EP (1) EP4469060A1 (enExample)
JP (1) JP2025508321A (enExample)
KR (2) KR102919268B1 (enExample)
CN (6) CN120754111A (enExample)
AU (1) AU2023210461A1 (enExample)
CA (1) CA3249575A1 (enExample)
CL (1) CL2024002201A1 (enExample)
CO (1) CO2024009565A2 (enExample)
GE (1) GEAP202416588A (enExample)
IL (1) IL314067A (enExample)
MX (1) MX2024009024A (enExample)
TW (2) TW202547520A (enExample)
WO (1) WO2023139285A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896719B2 (en) * 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
WO2026132451A1 (en) 2024-12-19 2026-06-25 Synthon B.V. Budesonide enteric capsule formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138716A1 (en) 2008-05-12 2009-11-19 Archimedes Development Limited Compositions for the oral delivery of corticosteroids
US20180256606A1 (en) 2002-10-29 2018-09-13 Evonik Roehm Gmbh Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123403A (en) 1977-06-27 1978-10-31 The Dow Chemical Company Continuous process for preparing aqueous polymer microsuspensions
US4502888A (en) 1982-12-13 1985-03-05 The Dow Chemical Company Aqueous dispersions of plasticized polymer particles
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
PT621032E (pt) 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
SE514128C2 (sv) * 1998-03-17 2001-01-08 Pharmalink Ab Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit
US6239120B1 (en) 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
DE10004939C1 (de) 2000-02-05 2001-08-23 Lothar Moerl Steuerbare Gasanströmeinrichtung für Strahlschichtapparate
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
ITRM20010614A1 (it) 2001-10-16 2003-04-16 Italchimici S P A Preparazione farmaceutica di una soluzione idro/propilenica di budesonide e suo procedimento di preparazione.
DE10162781A1 (de) 2001-12-20 2003-07-03 Glatt Ingtech Gmbh Strahlschichtapparat zur chargenweisen oder kontinuierlichen Prozessführung und Verfahren zum Betreiben eines Strahlschichtapparates
DE10214002A1 (de) 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
WO2004052607A1 (en) 2002-12-10 2004-06-24 Cps Orocel Llc Method of preparing biologically active formulations
DE10322062A1 (de) 2003-05-15 2004-12-02 Glatt Ingenieurtechnik Gmbh Verfahren und Vorrichtung zum Aufbringen von Flüssigkeiten in eine Feststoffströmung eines Strahlschichtapparates
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
AR041873A1 (es) 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
DE102005037630A1 (de) 2005-08-09 2007-02-15 Glatt Gmbh Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung
DE102005060393A1 (de) 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
CN101108171A (zh) 2006-07-17 2008-01-23 复旦大学 一种布地奈德肠溶缓释微丸及其制备方法
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2709561A1 (en) 2007-12-17 2009-06-25 Combinatorx, Incorporated Therapeutic regimens for the treatment of immunoinflammatory disorders
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
RU2578430C2 (ru) 2009-11-03 2016-03-27 Липидор Аб Композиция, образующая липидный слой, для нанесения на поверхность живого организма
WO2012116362A2 (en) 2011-02-25 2012-08-30 The Johns Hopkins University Chalcone derivatives as nrf2 activators
AU2012251135A1 (en) 2011-05-02 2013-11-07 Lipidor Ab Treatment of psoriasis
EP2591782A1 (en) 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof
WO2013078261A1 (en) 2011-11-22 2013-05-30 The University Of Maryland, Baltimore Treatment of muscular conditions and muscular dystrophies
EP2857399A1 (en) 2013-10-03 2015-04-08 GenKyoTex SA Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction
IN2013MU03373A (enExample) 2013-10-25 2015-07-17 Cadila Healthcare Ltd
CN112006989A (zh) 2013-11-14 2020-12-01 立普妥公司 包含磷脂酰胆碱的可喷雾的局部用载体和组合物
WO2015071812A1 (en) 2013-11-18 2015-05-21 Wockhardt Limited Solid oral modified-release composition comprising budesonide or salt thereof
GB201419257D0 (en) 2014-10-29 2014-12-10 Jagotec Ag Pharmaceutical compositions
EP3034500A1 (en) 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
US20190125678A1 (en) 2015-01-30 2019-05-02 Mylan, Inc. Sustained-Release Oral Dosage Forms for Low Aqueous Solubility Compounds
EP3098220A1 (en) 2015-05-28 2016-11-30 GenKyoTex SA Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof
JP2018530535A (ja) 2015-09-11 2018-10-18 サン・ファーマシューティカル・インダストリーズ・リミテッド ブデゾニドの経口医薬剤形
UY36948A (es) 2015-10-13 2017-05-31 Flexion Therapeutics Inc Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial
CN105663091A (zh) 2016-01-28 2016-06-15 上海信谊百路达药业有限公司 一种布地奈德肠溶缓释胶囊及其制备方法
US11590084B2 (en) 2016-05-02 2023-02-28 Roman Bielski Microcapsules for controlled delivery of an active pharmaceutical ingredient
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
JP2021515034A (ja) 2018-02-22 2021-06-17 アビオール、インコーポレイテッド 経粘膜フィルム組成物ならびにそれを作製及び使用する方法
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
EP3628669A1 (en) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
CN110507627B (zh) 2019-09-29 2021-11-02 重庆医药高等专科学校 一种布地奈德的口服控释药物组合物
WO2021127003A1 (en) 2019-12-16 2021-06-24 Children's Medical Center Corporation Treating heart disease in muscular dystrophy patients
CN112999229B (zh) 2019-12-19 2023-01-24 江苏恒瑞医药股份有限公司 一种包含布地奈德的口服药物组合物
WO2022222972A1 (zh) 2021-04-20 2022-10-27 江苏恒瑞医药股份有限公司 用于药物特定递送的胶囊及其制备方法
CN117157079A (zh) 2021-04-20 2023-12-01 江苏恒瑞医药股份有限公司 一种口服肠溶皮质类固醇的药物组合物
CN115737597A (zh) 2021-09-02 2023-03-07 江苏豪森药业集团有限公司 一种口服的肠溶速释药物组合物、制备方法及其应用
US20240033225A1 (en) * 2022-01-24 2024-02-01 Calliditas Therapeutics Ab Pharmaceutical compositions
US11896719B2 (en) * 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180256606A1 (en) 2002-10-29 2018-09-13 Evonik Roehm Gmbh Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers
WO2009138716A1 (en) 2008-05-12 2009-11-19 Archimedes Development Limited Compositions for the oral delivery of corticosteroids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Calliditas Therapeutics: "Prospectus" pp. 105-114 (2020.06.04)
The Lancet 389:10084 (2017.03.28)

Also Published As

Publication number Publication date
TW202339765A (zh) 2023-10-16
MX2024009024A (es) 2024-11-08
US20250312283A1 (en) 2025-10-09
US20240173264A1 (en) 2024-05-30
CN120053463A (zh) 2025-05-30
US12311057B2 (en) 2025-05-27
GEAP202416588A (en) 2024-11-25
US20240122863A1 (en) 2024-04-18
US20250381147A1 (en) 2025-12-18
US12171882B2 (en) 2024-12-24
US20250268835A1 (en) 2025-08-28
IL314067A (en) 2024-09-01
WO2023139285A1 (en) 2023-07-27
JP2025508321A (ja) 2025-03-26
US12171883B2 (en) 2024-12-24
CO2024009565A2 (es) 2024-09-19
CN121774982A (zh) 2026-04-03
EP4469060A1 (en) 2024-12-04
AU2023210461A1 (en) 2024-07-18
US11896719B2 (en) 2024-02-13
TWI896928B (zh) 2025-09-11
US20250057775A1 (en) 2025-02-20
TW202547520A (zh) 2025-12-16
CN120754112A (zh) 2025-10-10
CN120754113A (zh) 2025-10-10
KR20240141771A (ko) 2024-09-27
KR20250008979A (ko) 2025-01-16
US20230293444A1 (en) 2023-09-21
US20250255824A1 (en) 2025-08-14
CA3249575A1 (en) 2023-07-27
CL2024002201A1 (es) 2025-01-03
US20250312282A1 (en) 2025-10-09
US20250381146A1 (en) 2025-12-18
CN121796407A (zh) 2026-04-07
CN120754111A (zh) 2025-10-10

Similar Documents

Publication Publication Date Title
US12311057B2 (en) Pharmaceutical compositions
US20240033225A1 (en) Pharmaceutical compositions
CN110996915B (zh) 考来烯胺丸粒、口服考来烯胺制剂及其用途
CN108601745B (zh) 口服考来烯胺制剂及其用途
JP2020530448A (ja) コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CN102869349A (zh) 耐酒精的肠溶药物组合物
TW202140002A (zh) 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑
WO2009080030A1 (en) Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
CN118591376A (zh) 用于治疗IgA肾病的包含布地奈德的药物组合物
HK40125809A (en) Pharmaceutical composition comprising budesonide for treating iga nephropathy
HK40111255A (en) Pharmaceutical composition comprising budesonide for treating iga nephropathy
BR122026001808A2 (pt) Composições farmacêuticas que compreendem budesonida para tratar nefropatia por iga
WO2023133607A1 (en) Compositions comprising a chemokine receptor pathway inhibitor
TW201022215A (en) Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof, and methods for preparing and using same
김태광 In vitro and in vivo evaluation of solid dosage form: fixed-dose combination tablet and amorphous solid dispersion formulation
JP2025088773A (ja) 回腸へのターゲットデリバリーによる内毒素キレート剤の製造および代謝疾患の治療に関する応用
EA049118B1 (ru) Применение группы маркеров для диагностики и коррекции лечения первичного билиарного холангита, фармацевтическая композиция и твердая дозированная форма для лечения первичного билиарного холангита
JP4821607B2 (ja) 水難溶性薬物配合固形製剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)